# Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

> **NCT06553456** · PHASE2,PHASE3 · COMPLETED · sponsor: **Protgen Ltd** · enrollment: 390 (actual)

## Conditions studied

- Cirrhotic Ascites

## Interventions

- **DRUG:** Recombinant Human Serum Albumin
- **DRUG:** Human Serum Albumin

## Key facts

- **NCT ID:** NCT06553456
- **Lead sponsor:** Protgen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-19
- **Primary completion:** 2025-05-14
- **Final completion:** 2025-05-14
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06553456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06553456, "Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06553456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*